Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 15,625 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $37.51 on Friday. The firm has a market cap of $2.06 billion, a P/E ratio of -18.30 and a beta of 0.99. Vera Therapeutics, Inc. has a twelve month low of $9.24 and a twelve month high of $50.78. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $37.00 and a 200 day moving average of $39.24.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, research analysts expect that Vera Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund grew its stake in shares of Vera Therapeutics by 55.5% in the fourth quarter. New York State Common Retirement Fund now owns 17,491 shares of the company’s stock worth $269,000 after acquiring an additional 6,244 shares during the period. Crestline Management LP raised its stake in Vera Therapeutics by 32.4% during the 4th quarter. Crestline Management LP now owns 60,069 shares of the company’s stock valued at $924,000 after buying an additional 14,689 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Vera Therapeutics by 25.2% during the 4th quarter. Rafferty Asset Management LLC now owns 170,758 shares of the company’s stock valued at $2,626,000 after buying an additional 34,381 shares during the period. Schroder Investment Management Group bought a new position in shares of Vera Therapeutics during the 4th quarter valued at $17,087,000. Finally, Pale Fire Capital SE purchased a new position in shares of Vera Therapeutics in the 4th quarter worth $252,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VERA shares. Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a report on Friday, September 6th. JPMorgan Chase & Co. boosted their price target on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $51.75.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.